“The existing condition has exposed some structural weaknesses in the EU’s medicines source chain and a higher dependence on non-EU nations around the world for active pharmaceutical ingredients,” Kyriakides mentioned. She proposed that offer chain troubles be tackled in an EU pharmaceutical tactic